AstraZeneca to start phase III trials of pain product
10 September 2007 00:00 in Pharmaceutical Company Product News
AstraZeneca is to start the third phase of tests on a new pain product, it has emerged.
Working in conjunction with Pozen, the company is to begin trials on PN400 during the third quarter of this year, with a United States submission having a target currently for the first half of 2009.
The announcement comes as the two firms have modified certain terms of the collaboration and licence agreement signed in August last year.
Tony Zook, president and chief executive officer of AstraZeneca, said: "Millions of people worldwide suffer from arthritis and we are excited about the prospect of developing and bringing an important new therapy to these patients."
He added that PN400 "represents an important product development opportunity" for the company as it looks to introduce new pain medicines to the public.
The product is targeted at those requiring chronic non-steroidal anti-inflammation drug treatment for arthritis pain and who are at consequent risk of gastric ulcers.
Although both will contribute scientific, development and regulatory expertise, in addition to funding, Pozen will be responsible for development and regulatory filings within the United States, with AstraZeneca covering other activities taking place elsewhere in the world.
AstraZeneca claims to be a leading pharmaceutical company, producing a range of medicines and with interests in more than 100 countries.
Other news stories from 10/09/2007
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency